KLF5 and triple-A syndrome: To identify that Klf5 expression is either beneficial or detrimental to AAA development and progression, we pharmacologically suppressed the expression of Klf5 by injecting intraperitoneally ML264 into mice infused with Ang II for 14 days (early stage) and 42 days (early+late stage).